Evidence map›Paper›PMID 39438790›Full record

ArticleBMC cardiovascular disorders2024

The role of hemoglobin A1c as a predictor of major adverse cardiovascular events in patients with type 2 diabetes mellitus after percutaneous coronary intervention: a case-cohort study.

Babak Bagheri, Rozita Jalalian, Farima Sadat Mousavi, Soheil Azizi, Abbas Alipour, Fatemeh Mousavi, Erfan Ghadirzadeh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cardiovascular disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Babak BagheriDepartment of Cardiology, Faculty of Medicine, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran.ORCID 0000-0002-5133-2481
Rozita JalalianDepartment of Cardiology, Faculty of Medicine, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran.ORCID 0000-0001-9721-4950
Farima Sadat MousaviDepartment of Cardiology, Faculty of Medicine, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran. sf.musavi.k@gmail.com.ORCID 0000-0003-0654-5370
Soheil AziziDepartment of Laboratory Sciences, Faculty of Paramedicine, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran.ORCID 0000-0002-8802-4255
Abbas AlipourDepartment of Community Medicine, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.ORCID 0009-0006-2571-4319
Fatemeh MousaviSchool of Medicine, Mazandaran University of Medical Sciences, Mazandaran, Sari, Iran.ORCID 0000-0001-8325-5110
Erfan GhadirzadehCardiovascular Research Center, Mazandaran University of Medical Sciences, Mazandaran, Sari, Iran. er.ghadirzadeh@gmail.com.ORCID 0000-0002-3903-0464

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFew studies have investigated the potential predictive value of glycosylated hemoglobin A (HbA1c) and clinical outcomes in diabetic patients after percutaneous coronary intervention (PCI), and the results of the reports have often been inconclusive and contradictory. We have organized a study to investigate the relationship between HbA1c and the occurrence of major adverse cardiovascular events (MACE) in diabetic patients after PCI.

methodsThis case-cohort study was conducted on 563 diabetic patients who underwent PCI. All studied patients had an HbA1c level measured within 24 h before angioplasty. All patients were followed for six months regarding the occurrence of MACE, and the HbA1c level was measured again at the end of the sixth month of follow-up. In the case of MACE, the subjects were considered the case group, and other non-MACE patients were included in the control group.

results505 patients remained in the study at the end of follow-up. MACE occurred in 23 (4.6%) patients during the first month and in 57 (11.3%) patients by the end of the sixth month. Baseline HbA1c was an independent predictor of MACE and mortality at the end of month-6 (P = 0.008 and 0.001, respectively).

conclusionsThe level of HbA1c at the time of admission has a significant predictive value for the occurrence of MACE in diabetic patients who undergo PCI. However, post-PCI glycemic control may not effectively reduce the risk of MACE in this population. CLINICAL

trial registrationNot applicable.

Indexed as

BiomarkersDiabetes Mellitus, Type 2Glycated HemoglobinPercutaneous Coronary InterventionAgedCase-Control StudiesCoronary Artery DiseaseFemaleHumansMaleMiddle AgedPredictive Value of TestsRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeBiomarkersGlycated Hemoglobinhemoglobin A1c protein, humanAcute coronary syndromeDiabetes mellitusGlycated hemoglobinHbA1cMACEMajor adverse cardiovascular eventsMortalityPercutaneous coronary intervention

Identifiers

PMID39438790
PMCPMC11495103

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.